Chinese NMPA accepts New Drug Application for Illuccix for prostate cancer imaging – Telix Pharmaceuticals
Telix Pharmaceuticals Limited announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (NDA) for… read more.




